These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22532859)

  • 81. Estimated Investment Need to Increase England's Capacity to Diagnose Eligibility for an Alzheimer's Treatment to G7 Average Capacity Levels.
    Mattke S; Shi Z; Hanson M; Mitchell S; Lynch C; MacLean Kalonji K; Lanman L
    J Prev Alzheimers Dis; 2024; 11(4):1022-1029. PubMed ID: 39044513
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Two-tiered approach to MRI for headache: a cost-effective way to use an expensive technology.
    Sharma A; Reis M; Parsons MS; Wippold FJ; Chrisinger J; Schwedt TJ; Pilgram TK
    AJR Am J Roentgenol; 2013 Jul; 201(1):W75-80. PubMed ID: 23789700
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.
    Wimo A; Belger M; Bon J; Jessen F; Dumas A; Kramberger MG; Jamilis L; Johansson G; Rodrigo Salas A; Rodríguez Gómez O; Sannemann L; Stoekenbroek M; Gurruchaga Telleria M; Valero S; Vermunt L; Waterink L; Winblad B; Visser PJ; Zwan M; Boada M;
    J Alzheimers Dis; 2021; 83(3):1149-1159. PubMed ID: 34420954
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Adaptive data-driven selection of sequences of biological and cognitive markers in pre-clinical diagnosis of dementia.
    Wyss P; Ginsbourger D; Shou H; Davatzikos C; Klöppel S; Abdulkadir A
    Sci Rep; 2023 Apr; 13(1):6406. PubMed ID: 37076487
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.
    Saumier D; Aisen PS; Gauthier S; Vellas B; Ferris SH; Duong A; Suhy J; Oh J; Lau W; Garceau D; Haine D; Sampalis J
    J Nutr Health Aging; 2009 Apr; 13(4):370-2. PubMed ID: 19300884
    [No Abstract]   [Full Text] [Related]  

  • 86. Effect of mortality in cost-effectiveness modeling of disease-modifying treatment for Alzheimer's disease.
    Aye S; Jönsson L; Gustavsson A; Tate A; Ptacek SG; Eriksdotter M
    Alzheimers Dement (Amst); 2023; 15(1):e12422. PubMed ID: 37009338
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Structural MRI for the Early Diagnosis of Alzheimer Disease in Patients with MCI.
    Butler E; Mounsey A
    Am Fam Physician; 2021 Mar; 103(5):273-274. PubMed ID: 33630555
    [No Abstract]   [Full Text] [Related]  

  • 88. Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis.
    Pandey G; Ramakrishnan V
    Biophys Rev; 2020 Oct; 12(5):1175-1186. PubMed ID: 32930962
    [TBL] [Abstract][Full Text] [Related]  

  • 89. An EEG-fNIRS hybridization technique in the four-class classification of alzheimer's disease.
    Cicalese PA; Li R; Ahmadi MB; Wang C; Francis JT; Selvaraj S; Schulz PE; Zhang Y
    J Neurosci Methods; 2020 Apr; 336():108618. PubMed ID: 32045572
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.
    Kim H; Han H
    Bioinformation; 2018; 14(4):167-180. PubMed ID: 29983487
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis.
    Michaud TL; Kane RL; McCarten JR; Gaugler JE; Nyman JA; Kuntz KM
    Pharmacoecon Open; 2018 Sep; 2(3):309-323. PubMed ID: 29623628
    [TBL] [Abstract][Full Text] [Related]  

  • 92. ATP Binding Cassette Subfamily A Member 2 (ABCA2) Expression and Methylation are Associated with Alzheimer's Disease.
    Hu W; Lin X; Zhang H; Zhao N
    Med Sci Monit; 2017 Dec; 23():5851-5861. PubMed ID: 29224028
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.
    Lewczuk P; Riederer P; O'Bryant SE; Verbeek MM; Dubois B; Visser PJ; Jellinger KA; Engelborghs S; Ramirez A; Parnetti L; Jack CR; Teunissen CE; Hampel H; Lleó A; Jessen F; Glodzik L; de Leon MJ; Fagan AM; Molinuevo JL; Jansen WJ; Winblad B; Shaw LM; Andreasson U; Otto M; Mollenhauer B; Wiltfang J; Turner MR; Zerr I; Handels R; Thompson AG; Johansson G; Ermann N; Trojanowski JQ; Karaca I; Wagner H; Oeckl P; van Waalwijk van Doorn L; Bjerke M; Kapogiannis D; Kuiperij HB; Farotti L; Li Y; Gordon BA; Epelbaum S; Vos SJB; Klijn CJM; Van Nostrand WE; Minguillon C; Schmitz M; Gallo C; Lopez Mato A; Thibaut F; Lista S; Alcolea D; Zetterberg H; Blennow K; Kornhuber J;
    World J Biol Psychiatry; 2018 Jun; 19(4):244-328. PubMed ID: 29076399
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status.
    Sood S; Gallagher IJ; Lunnon K; Rullman E; Keohane A; Crossland H; Phillips BE; Cederholm T; Jensen T; van Loon LJ; Lannfelt L; Kraus WE; Atherton PJ; Howard R; Gustafsson T; Hodges A; Timmons JA
    Genome Biol; 2015 Sep; 16(1):185. PubMed ID: 26343147
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies.
    Krol M; Papenburg J; van Exel J
    Pharmacoeconomics; 2015 Feb; 33(2):123-35. PubMed ID: 25315368
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Exploring the functional brain network of Alzheimer's disease: based on the computational experiment.
    Li Y; Qin Y; Chen X; Li W
    PLoS One; 2013; 8(9):e73186. PubMed ID: 24019905
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer's disease.
    Biasutti M; Dufour N; Ferroud C; Dab W; Temime L
    PLoS One; 2012; 7(4):e35559. PubMed ID: 22532859
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S; Passamonti L; Duggento A; Liò P; Toschi N;
    Neuroimage; 2019 Apr; 189():276-287. PubMed ID: 30654174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.